Clinical Trial: Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Allergic Fungal Rhinosinusitis
Study Type: INTERVENTIONAL
Official Title: A Randomized, 52-week Treatment Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosin
Brief Summary:
The purpose of this study is to find a more effective treatment for allergic fungal rhinosinusitis (AFRS).Most people suffering from nasal polyps have elevated levels of white blood cells called eosinophils that are involved in inflammation of the air passages.Despite appropriate treatment with oral/topical corticosteroids, saline irrigations, and surgery, nasal polyps return frequently within months of surgery.Certain proteins made by the body called interleukins, appear to play a major role in the survival…
Read more